Altered TNFAIP3 mRNA expression in peripheral blood mononuclear cells from patients with rheumatoid arthritis

Wang,Zhaoyan; Zhang,Zongliang; Yuan,Jiangshui; Li,Li

doi:10.3892/br.2015.486

Altered TNFAIP3 mRNA expression in peripheral blood mononuclear cells from patients with rheumatoid arthritis

Authors:
- Zhaoyan Wang
- Zongliang Zhang
- Jiangshui Yuan
- Li Li
View Affiliations

Affiliations: Clinical Laboratory, Qingdao Municipal Hospital, Qingdao, Shandong 266011, P.R. China, Department of Urology, Qingdao Municipal Hospital, Qingdao, Shandong 266011, P.R. China
Published online on: June 30, 2015 https://doi.org/10.3892/br.2015.486
Pages: 675-680

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The tumor necrosis factor α-induced protein-3 (TNFAIP3) gene functions in negative immunoregulation and its single‑nucleotide polymorphisms (SNPs) are associated with rheumatoid arthritis (RA) disease. However, its expression level in immune cells from RA patients remains unclear. The aim of the present study was to investigate whether the expression of TNFAIP3 is changed in patients with RA. Reverse transcription‑quantitative polymerase chain reaction analysis was used to determine TNFAIP3 mRNA expression in peripheral blood mononuclear cells (PBMCs) from patients with RA and healthy controls. TNFAIP3 expression was decreased in RA patients compared with the healthy controls. The expression level of the TNFAIP3 gene negatively correlated with the RA score, anti‑cyclic citrullinated peptide (CCP) antibody levels and C‑reactive protein levels. Furthermore, RA patients with positive results of anti‑CCP antibodies had a lower expression of TNFAIP3 than those without anti‑CCP antibodies. In conclusion, the present results suggest that the insufficient expression of the TNFAIP3 gene in PBMCs may correlate with the diagnosis of RA.

View Figures

View References

1	Firestein GS: Evolving concepts of rheumatoid arthritis. Nature. 423:356–361. 2003. View Article : Google Scholar : PubMed/NCBI
2	Iwamoto T, Okamoto H, Toyama Y and Momohara S: Molecular aspects of rheumatoid arthritis: Chemokines in the joints of patients. FEBS J. 275:4448–4455. 2008. View Article : Google Scholar : PubMed/NCBI
3	Li D, Wang L, Fan Y, Song L, Guo C, Zhu F, Zhang L and Shi Y: Down-regulation of A20 mRNA expression in peripheral blood mononuclear cells from patients with systemic lupus erythematosus. J Clin Immunol. 32:1287–1291. 2012. View Article : Google Scholar : PubMed/NCBI
4	Apostolidis SA, Lieberman LA, Kis-Toth K, Crispín JC and Tsokos GC: The dysregulation of cytokine networks in systemic lupus erythematosus. J Interferon Cytokine Res. 31:769–779. 2011. View Article : Google Scholar : PubMed/NCBI
5	Geiler J, Buch M and McDermott MF: Anti-TNF treatment in rheumatoid arthritis. Curr Pharm Des. 17:3141–3154. 2011. View Article : Google Scholar : PubMed/NCBI
6	Silverman N and Maniatis T: NF-kappaB signaling pathways in mammalian and insect innate immunity. Genes Dev. 15:2321–2342. 2001. View Article : Google Scholar : PubMed/NCBI
7	Verma IM, Stevenson JK, Schwarz EM, Van Antwerp D and Miyamoto S: Rel/NF-kappa B/I kappa B family: Intimate tales of association and dissociation. Genes Dev. 9:2723–2735. 1995. View Article : Google Scholar : PubMed/NCBI
8	Cavalcante LO, Melo MR, Dinis VG, Castro RB, Souza BD and Longui CA: Quantitation of glucocorticoid receptor alpha and NF-κB pathway mRNA and its correlation with disease activity in rheumatoid arthritis patients. Genet Mol Res. 9:2300–2310. 2010. View Article : Google Scholar : PubMed/NCBI
9	Criswell LA: Gene discovery in rheumatoid arthritis highlights the CD40/NF-kappaB signaling pathway in disease pathogenesis. Immunol Rev. 233:55–61. 2010. View Article : Google Scholar : PubMed/NCBI
10	Simmonds RE and Foxwell BM: Signalling, inflammation and arthritis: NF-kappaB and its relevance to arthritis and inflammation. Rheumatology (Oxford). 47:584–590. 2008. View Article : Google Scholar : PubMed/NCBI
11	Elsby LM, Orozco G, Denton J, Worthington J, Ray DW and Donn RP: Functional evaluation of TNFAIP3 (A20) in rheumatoid arthritis. Clin Exp Rheumatol. 28:708–714. 2010.PubMed/NCBI
12	Vereecke L, Beyaert R and van Loo G: The ubiquitin-editing enzyme A20 (TNFAIP3) is a central regulator of immunopathology. Trends Immunol. 30:383–391. 2009. View Article : Google Scholar : PubMed/NCBI
13	Coornaert B, Carpentier I and Beyaert R: A20: Central gatekeeper in inflammation and immunity. J Biol Chem. 284:8217–8221. 2009. View Article : Google Scholar : PubMed/NCBI
14	Kingeter LM, Paul S, Maynard SK, Cartwright NG and Schaefer BC: Cutting edge: TCR ligation triggers digital activation of NF-kappaB. J Immunol. 185:4520–4524. 2010. View Article : Google Scholar : PubMed/NCBI
15	Düwel M, Welteke V, Oeckinghaus A, Baens M, Kloo B, Ferch U, Darnay BG, Ruland J, Marynen P and Krappmann D: A20 negatively regulates T cell receptor signaling to NF-kappaB by cleaving Malt1 ubiquitin chains. J Immunol. 182:7718–7728. 2009. View Article : Google Scholar : PubMed/NCBI
16	Lee EG, Boone DL, Chai S, Libby SL, Chien M, Lodolce JP and Ma A: Failure to regulate TNF-induced NF-kappaB and cell death responses in A20-deficient mice. Science. 289:2350–2354. 2000. View Article : Google Scholar : PubMed/NCBI
17	Orozco G, Hinks A, Eyre S, et al Wellcome Trust Case Control Consortium; YEAR consortium: Combined effects of three independent SNPs greatly increase the risk estimate for RA at 6q23. Hum Mol Genet. 18:2693–2699. 2009. View Article : Google Scholar : PubMed/NCBI
18	Musone SL, Taylor KE, Lu TT, Nititham J, Ferreira RC, Ortmann W, Shifrin N, Petri MA, Kamboh MI, Manzi S, et al: Multiple polymorphisms in the TNFAIP3 region are independently associated with systemic lupus erythematosus. Nat Genet. 40:1062–1064. 2008. View Article : Google Scholar : PubMed/NCBI
19	Thomson W, Barton A, Ke X, Eyre S, Hinks A, Bowes J, Donn R, Symmons D, Hider S, Bruce IN, et al Wellcome Trust Case Control Consortium; YEAR Consortium: Rheumatoid arthritis association at 6q23. Nat Genet. 39:1431–1433. 2007. View Article : Google Scholar : PubMed/NCBI
20	Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO III, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, et al: 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 62:2569–2581. 2010. View Article : Google Scholar : PubMed/NCBI
21	Hah YS, Lee YR, Jun JS, Lim HS, Kim HO, Jeong YG, Hur GM, Lee SY, Chung MJ, Park JW, et al: A20 suppresses inflammatory responses and bone destruction in human fibroblast-like synoviocytes and in mice with collagen-induced arthritis. Arthritis Rheum. 62:2313–2321. 2010. View Article : Google Scholar : PubMed/NCBI
22	Boone DL, Turer EE, Lee EG, Ahmad RC, Wheeler MT, Tsui C, Hurley P, Chien M, Chai S, Hitotsumatsu O, et al: The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses. Nat Immunol. 5:1052–1060. 2004. View Article : Google Scholar : PubMed/NCBI
23	Renner F and Schmitz ML: Autoregulatory feedback loops terminating the NF-kappaB response. Trends Biochem Sci. 34:128–135. 2009. View Article : Google Scholar : PubMed/NCBI
24	Kato M, Sanada M, Kato I, et al: Frequent inactivation of A20 in B-cell lymphomas. Nature. 459:712–716. 2009. View Article : Google Scholar : PubMed/NCBI
25	Schmitz R, Hansmann ML, Bohle V, Martin-Subero JI, Hartmann S, Mechtersheimer G, Klapper W, Vater I, Giefing M, Gesk S, et al: TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma. J Exp Med. 206:981–989. 2009. View Article : Google Scholar : PubMed/NCBI
26	Heyninck K and Beyaert R: A20 inhibits NF-kappaB activation by dual ubiquitin-editing functions. Trends Biochem Sci. 30:1–4. 2005. View Article : Google Scholar : PubMed/NCBI
27	Tavares RM, Turer EE, Liu CL, Advincula R, Scapini P, Rhee L, Barrera J, Lowell CA, Utz PJ, Malynn BA, et al: The ubiquitin modifying enzyme A20 restricts B cell survival and prevents autoimmunity. Immunity. 33:181–191. 2010. View Article : Google Scholar : PubMed/NCBI
28	Kool M, van Loo G, Waelput W, De Prijck S, Muskens F, Sze M, van Praet J, Branco-Madeira F, Janssens S, Reizis B, et al: The ubiquitin-editing protein A20 prevents dendritic cell activation, recognition of apoptotic cells, and systemic autoimmunity. Immunity. 35:82–96. 2011. View Article : Google Scholar : PubMed/NCBI
29	Hövelmeyer N, Reissig S, Xuan NT, Adams-Quack P, Lukas D, Nikolaev A, Schlüter D and Waisman A: A20 deficiency in B cells enhances B-cell proliferation and results in the development of autoantibodies. Eur J Immunol. 41:595–601. 2011. View Article : Google Scholar : PubMed/NCBI
30	Handel ML, McMorrow LB and Gravallese EM: Nuclear factor-kappa B in rheumatoid synovium. Localization of p50 and p65. Arthritis Rheum. 38:1762–1770. 1995. View Article : Google Scholar : PubMed/NCBI
31	Marok R, Winyard PG, Coumbe A, Kus ML, Gaffney K, Blades S, Mapp PI, Morris CJ, Blake DR, Kaltschmidt C, et al: Activation of the transcription factor nuclear factor-kappaB in human inflamed synovial tissue. Arthritis Rheum. 39:583–591. 1996. View Article : Google Scholar : PubMed/NCBI
32	Brown KD, Claudio E and Siebenlist U: The roles of the classical and alternative nuclear factor-kappaB pathways: Potential implications for autoimmunity and rheumatoid arthritis. Arthritis Res Ther. 10:2122008. View Article : Google Scholar : PubMed/NCBI
33	Vereecke L, Beyaert R and van Loo G: Genetic relationships between A20/TNFAIP3, chronic inflammation and autoimmune disease. Biochem Soc Trans. 39:1086–1091. 2011. View Article : Google Scholar : PubMed/NCBI
34	Matmati M, Jacques P, Maelfait J, Verheugen E, Kool M, Sze M, Geboes L, Louagie E, Mc Guire C, Vereecke L, et al: A20 (TNFAIP3) deficiency in myeloid cells triggers erosive polyarthritis resembling rheumatoid arthritis. Nat Genet. 43:908–912. 2011. View Article : Google Scholar : PubMed/NCBI
35	Boonyasrisawat W, Eberle D, Bacci S, Zhang YY, Nolan D, Gervino EV, Johnstone MT, Trischitta V, Shoelson SE and Doria A: Tag polymorphisms at the A20 (TNFAIP3) locus are associated with lower gene expression and increased risk of coronary artery disease in type 2 diabetes. Diabetes. 56:499–505. 2007. View Article : Google Scholar : PubMed/NCBI
36	Tejasvi T, Stuart PE, Chandran V, Voorhees JJ, Gladman DD, Rahman P, Elder JT and Nair RP: TNFAIP3 gene polymorphisms are associated with response to TNF blockade in psoriasis. J Invest Dermatol. 132:593–600. 2012. View Article : Google Scholar : PubMed/NCBI
37	Maxwell JR, Gowers IR, Kuet KP, Barton A, Worthington J and Wilson AG: Expression of the autoimmunity associated TNFAIP3 is increased in rheumatoid arthritis but does not differ according to genotype at 6q23. Rheumatology (Oxford). 51:1514–1515. 2012. View Article : Google Scholar : PubMed/NCBI
38	Plenge RM, Cotsapas C, Davies L, Price AL, de Bakker PI, Maller J, Pe'er I, Burtt NP, Blumenstiel B, DeFelice M, et al: Two independent alleles at 6q23 associated with risk of rheumatoid arthritis. Nat Genet. 39:1477–1482. 2007. View Article : Google Scholar : PubMed/NCBI
39	Frenzel LP, Claus R, Plume N, Schwamb J, Konermann C, Pallasch CP, Claasen J, Brinker R, Wollnik B, Plass C, et al: Sustained NF-kappaB activity in chronic lymphocytic leukemia is independent of genetic and epigenetic alterations in the TNFAIP3 (A20) locus. Int J Cancer. 128:2495–2500. 2011. View Article : Google Scholar : PubMed/NCBI